A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms PANDORE
- 02 Jan 2019 Planned End Date changed from 1 May 2019 to 1 Oct 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated